Table 4.
Association of admission sex and mineralocorticoid hormone metabolite levels with short- and long-term all-cause mortality in CAP, entire cohort
| Entire cohort (N = 285) | All-cause mortality timepoint | |||||
|---|---|---|---|---|---|---|
| 30 days | 3 years | 6 years | ||||
| HR (95%CI) | p value | HR (95%CI) | p value | HR (95%CI) | p value | |
| Progesterone | ||||||
| Cox regression analyses | 0.72 (95%CI 0.15–3.34) | p = 0.666 | 0.49 (95%CI 0.28–0.88) | p = 0.016 | 0.61 (95%CI 0.39–0.97) | p = 0.037 |
| 17-OH-Progesterone | ||||||
| Cox regression analyses | 0.73 (95%CI 0.39–1.36) | p = 0.324 | 0.70 (95%CI 0.52–0.96) | p = 0.027 | 0.75 (95%CI 0.57–0.98) | p = 0.034 |
| Aldosterone | ||||||
| Cox regression analyses | 1.41 (95%CI 0.56–3.56) | p = 0.461 | 0.93 (95%CI 0.62–1.37) | p = 0.700 | 0.81 (95%CI 0.60–1.11) | p = 0.200 |
| DHEA | ||||||
| Cox regression analyses | 45.73 (95%CI 0.01–295,289.2) | p = 0.393 | 0.46 (95%CI 0.17–1.25) | p = 0.126 | 0.64 (95%CI 0.36–1.21) | p = 0.119 |
| DHEA-S | ||||||
| Cox regression analyses | 0.57 (95%CI 0.01–25.17) | p = 0.768 | 0.75 (95%CI 0.50–1.12) | p = 0.155 | 0.72 (95%CI 0.51–1.01) | p = 0.060 |
| Androstenedione | ||||||
| Cox regression analyses | 2.93 (95%CI 0.74–11.62) | p = 0.126 | 0.79 (95%CI 0.56–1.12) | p = 0.180 | 0.90 (95%CI 0.67–1.21) | p = 0.478 |
| Testosterone | ||||||
| Cox regression analyses | 0.80 (95%CI 0.30–2.15) | p = 0.658 | 1.10 (95%CI 0.71–1.71) | p = 0.656 | 1.03 (95%CI 0.71–1.51) | p = 0.867 |
| Dihydrotestosterone | ||||||
| Cox regression analyses | 2.45 (95%CI 0.39–15.42) | p = 0.339 | 1.85 (95%CI 0.93–3.67) | p = 0.078 | 1.78 (95%CI 1.03–3.09) | p = 0.040 |
Data for multivariate Cox regression models are presented as HR (95% CI), p value; p values are considered statistically significant at p < 0.05. Bold values indicate statistical significance. All hormone levels were log-transformed and thus the HR corresponds to a 10-fold increase in these levels. CI confidence interval, DHEA dehydroepiandrosterone, DHEA-S dehydroepiandrosterone sulfate, HR hazard ratio
The multivariate model is adjusted for age and comorbidities (coronary artery disease, cerebrovascular disease, chronic kidney disease, neoplastic disease)